Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Jose R. Conejo-Garcia, inventor of their ovarian cancer CAR-T technology, will deliver the opening keynote at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium on September 20, 2024. Dr. Conejo-Garcia will discuss Anixa's chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) found exclusively on ovarian granulosa cells.
The presentation will cover the ongoing Phase 1 clinical trial of this technology, which has shown promising results with the treatment appearing safe and well-tolerated, and some patients exhibiting tumor necrosis. Anixa holds an exclusive worldwide license for this technology from The Wistar Institute and is developing it in partnership with Moffitt Cancer Center.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato che il Dr. Jose R. Conejo-Garcia, inventore della loro tecnologia CAR-T per il cancro ovarico, terrà il discorso inaugurale al 15° Simposio Biennale sulla Ricerca sul Cancro Ovarico organizzato dal Rivkin Center-AACR il 20 settembre 2024. Il Dr. Conejo-Garcia discuterà della terapia con recettore endogeno chimerico per cellule T (CER-T) di Anixa, che mira al recettore dell'ormone follicolo-stimolante (FSHR) presente esclusivamente sulle cellule della granulosa ovarica.
La presentazione coprirà il trial clinico di Fase 1 di questa tecnologia, che ha mostrato risultati promettenti, con il trattamento che appare sicuro e ben tollerato, e alcuni pazienti che mostrano necrosi tumorale. Anixa detiene una licenza mondiale esclusiva per questa tecnologia dall'Istituto Wistar e la sta sviluppando in collaborazione con il Moffitt Cancer Center.
Anixa Biosciences (NASDAQ: ANIX) anunció que el Dr. Jose R. Conejo-Garcia, inventor de su tecnología CAR-T para el cáncer de ovario, será el encargado de dar la conferencia inaugural en el 15º Simposio Bienal de Investigación sobre el Cáncer de Ovario del Rivkin Center-AACR el 20 de septiembre de 2024. El Dr. Conejo-Garcia discutirá sobre la terapia con receptor endógeno quimérico para células T (CER-T) de Anixa, que se dirige al receptor de hormona estimulante del folículo (FSHR) que se encuentra exclusivamente en las células de la granulosa ovárica.
La presentación cubrirá el ensayo clínico de Fase 1 de esta tecnología, que ha mostrado resultados prometedores, con el tratamiento que parece seguro y bien tolerado, y algunos pacientes presentan necrosis tumoral. Anixa tiene una licencia mundial exclusiva para esta tecnología del Instituto Wistar y la está desarrollando en asociación con el Moffitt Cancer Center.
Anixa 바이오사이언스(NASDAQ: ANIX)는 자사의 난소암 CAR-T 기술의 발명자인 Dr. Jose R. Conejo-Garcia가 2024년 9월 20일 Rivkin Center-AACR 제15회 난소암 연구 심포지엄에서 개막 기조연설을 할 것이라고 발표했습니다. Conejo-Garcia 박사는 난소의 그라놀로사 세포에서 독점적으로 발견되는 난포 자극 호르몬 수용체(FSHR)를 표적으로 하는 Anixa의 키메라 내분비 수용체-T 세포(CER-T) 치료법에 대해 논의할 것입니다.
이번 발표에서는 이 기술의 1상 임상 시험 진행 상황을 다룰 것이며, 이 치료법은 안전하고 잘 견디는 것으로 나타났고, 일부 환자에서는 종양이 괴사한 사례도 보였습니다. Anixa는 Wistar 연구소로부터 이 기술에 대한 독점 전 세계 라이센스를 보유하고 있으며, Moffitt Cancer Center와 협력하여 개발하고 있습니다.
Anixa Biosciences (NASDAQ : ANIX) a annoncé que le Dr. Jose R. Conejo-Garcia, inventeur de leur technologie CAR-T pour le cancer de l'ovaire, prononcera le discours d'ouverture lors du 15e Symposium Biennal de Recherche sur le Cancer de l'Ovaire du Rivkin Center-AACR, le 20 septembre 2024. Le Dr. Conejo-Garcia abordera la thérapie par récepteur endocrinien chimérique pour cellules T (CER-T) d'Anixa, qui cible le récepteur de l'hormone folliculostimulante (FSHR) que l'on trouve exclusivement sur les cellules granulosa des ovaires.
La présentation couvrira l'essai clinique de Phase 1 de cette technologie, qui a montré des résultats prometteurs avec un traitement considéré comme sûr et bien toléré, et certains patients présentant une nécrose tumorale. Anixa possède une licence mondiale exclusive pour cette technologie délivrée par l'Institut Wistar et la développe en partenariat avec le Moffitt Cancer Center.
Anixa Biosciences (NASDAQ: ANIX) gab bekannt, dass Dr. Jose R. Conejo-Garcia, der Erfinder ihrer CAR-T-Technologie gegen Eierstockkrebs, die Eröffnungsrede beim 15. Biennalen Symposium zur Forschung über Eierstockkrebs des Rivkin Centers-AACR am 20. September 2024 halten wird. Dr. Conejo-Garcia wird über Anixas chimären endokrinen Rezeptor-T-Zelltherapie (CER-T) sprechen, die auf den ausschließlich auf den Granulosazellen der Eierstöcke vorkommenden follikelstimulierenden Hormonrezeptor (FSHR) abzielt.
Die Präsentation wird die laufende Phase-1-Studie dieser Technologie behandeln, die vielversprechende Ergebnisse gezeigt hat, wobei die Behandlung sicher und gut verträglich erscheint und einige Patienten Tumornecrose aufweisen. Anixa hält eine ausschließliche weltweite Lizenz für diese Technologie vom Wistar Institute und entwickelt sie in Partnerschaft mit dem Moffitt Cancer Center.
- Anixa's ovarian cancer CAR-T technology to be presented at a major cancer research symposium
- Ongoing Phase 1 clinical trial shows promising results with the treatment appearing safe and well-tolerated
- Some patients in the trial exhibiting tumor necrosis
- Exclusive worldwide license for the technology
- Partnership with Moffitt Cancer Center for development
- None.
During the keynote address, Dr. Conejo-Garcia will discuss Anixa's chimeric antigen receptor-T cell (CAR-T) technology, which is an autologous cell therapy comprised of engineered T cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor-T cell) therapy, a new type of CAR-T. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute. Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical trial of this technology.
"I am pleased to discuss this novel FSHR-mediated CAR-T technology at the Ovarian Cancer Research Symposium and to share ideas and advance the field of ovarian cancer research," stated Dr. Conejo-Garcia. "Anixa and its development partner, Moffitt Cancer Center, have been working together to advance this ovarian cancer therapy and we are excited about the clinical results to date—with the treatment appearing to be safe and well-tolerated, and some patients exhibiting tumor necrosis. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer."
More information about the event may be found at: https://rivkin.org/symposia/ocrs/.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-therapy-at-the-rivkin-center-aacr-15th-biennial-ovarian-cancer-research-symposium-302233678.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is Anixa Biosciences' (ANIX) new ovarian cancer treatment technology?
When and where will Anixa's (ANIX) ovarian cancer CAR-T technology be presented?
What are the initial results of Anixa Biosciences' (ANIX) Phase 1 clinical trial for ovarian cancer?
Who is Anixa Biosciences (ANIX) partnering with to develop their ovarian cancer therapy?
